Envoy Medical, Inc. (COCH) Stock Price & Analysis
Envoy Medical, Inc. (COCH) rose 0.26% to USD 0.66 as of July 25, 2026 at 13:44 UTC, according to Nexqual real-time market data.
COCH last closed at USD 0.66; the session ranged USD 0.65–0.69 on volume of 111,692 shares. Market capitalization is $51.04M, with a 52-week range of USD 0.36–1.89 (NCM). Source: Nexqual, July 25, 2026 at 13:44 UTC.
Key Statistics (as of July 25, 2026 at 13:44 UTC)
| Price | USD 0.66 |
|---|---|
| Change | ▲ 0.26% (up) |
| Previous Close | USD 0.66 |
| Open | USD 0.68 |
| Day Range | USD 0.65 – 0.69 |
| 52-Week Range | USD 0.36 – 1.89 |
| Volume | 111,692 shares |
| Market Cap | $51.04M |
| Exchange | NCM |
Technical Analysis (COCH)
Nexqual's technical model rates COCH "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 13:44 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 45.22 (neutral) |
| vs SMA50 | Below (USD 0.69) |
| MACD | -0 (negative) |
Analyst Ratings (COCH)
Wall Street analysts rate COCH "Strong Buy" based on 1 analysts, with a mean price target of USD 2.5 (range USD 2.5–2.5), per Nexqual as of July 25, 2026 at 13:44 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 2.5 |
| High Target | USD 2.5 |
| Low Target | USD 2.5 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (COCH)
| EPS Estimate | USD -0.09 |
|---|---|
| Revenue Estimate | $60,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.08 vs est -0.14 ▲ beat |
| 2025-09-30 | USD -0.35 vs est -0.29 ▼ miss |
| 2025-06-30 | USD -0.32 vs est -0.29 ▼ miss |
Source: Nexqual, July 25, 2026 at 13:44 UTC.
Financials & Fundamentals (COCH)
| Total Revenue | $234,000 |
|---|---|
| Revenue Growth (YoY) | -15.20% |
| Gross Margin | -229.49% |
| Operating Margin | -15279.49% |
| Profit Margin | +0.00% |
| Debt / Equity | 8.43 |
| Current Ratio | 2.27 |
| Total Cash | $25.25M |
| Total Debt | $889,000 |
| Free Cash Flow | $-7.91M |
Source: Nexqual, July 25, 2026 at 13:44 UTC.
Financial Health Score (COCH)
Nexqual rates Envoy Medical, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 13:44 UTC.
| Growth | Solid — Revenue +7% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $25M cash, no debt |
| Cash Flow | Weak — FCF negative: -$8M, burning cash |
| Efficiency | Mixed — No data |
Ownership (COCH)
| Insider Ownership | +40.50% |
|---|---|
| Institutional Ownership | +22.90% |
| Shares Outstanding | 77.02M |
| Float | 38.09M |
| Short % of Float | +1.92% |
Source: Nexqual, July 25, 2026 at 13:44 UTC.
Leadership (COCH)
Envoy Medical, Inc. is led by Brent T. Lucas (age 43), CEO & Director, per Nexqual as of July 25, 2026 at 13:44 UTC.
| CEO & Director | Brent T. Lucas (age 43) |
|---|---|
| Interim CFO & Principal Accounting Officer | Robert M. Potashnick (age 44) |
Major Backers & Investors (COCH)
Notable institutional backers of Envoy Medical, Inc. include Nantahala Capital Management, LLC, Bleichroeder LP, Dsg Capital Advisors, LLC , according to Nexqual as of July 25, 2026 at 13:44 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Nantahala Capital Management, LLC | 9.95% |
| Bleichroeder LP | 8.13% |
| Dsg Capital Advisors, LLC | 0.81% |
| Fidelity | 0.59% |
| Focus Partners Wealth | 0.28% |
| Arcus Capital Partners, Llc | 0.24% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.68% |
| Geode Capital | 0.68% |
| Northern Trust | 0.14% |
Source: Nexqual, July 25, 2026 at 13:44 UTC.
From Envoy Medical, Inc.'s Latest SEC 10-K Filing (filed 2026-03-23)
Key Strengths & Strategy (as disclosed to the SEC)
- Envoy Medical, Inc., a hearing health company, provides medical technologies across the hearing loss spectrum.
- The company's medical technologies are designed to shift the paradigm within the hearing industry and bring providers and patients the hearing devices desire.
- It offers personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| HWH | HWH International Inc. | USD 1.42 | ▲ 13.6% |
| MGIH | Millennium Group International | USD 1.62 | ▼ 2.41% |
| CCTG | CCSC Technology International H | USD 0.79 | ▼ 1.57% |
| AIMD | Ainos, Inc. | USD 1.4 | ▼ 9.09% |
| LRHC | La Rosa Holdings Corp. | USD 0.97 | ▲ 5.87% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 13:44 UTC. This page is informational and not investment advice.